View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML

DOD/DODOASHA RIN: 0720-AB83 Publication ID: Spring 2022 
Title: TRICARE Coverage of National Institute of Allergy and Infectious Disease Coronavirus Disease 2019 Clinical Trials 

This final rule will publish under the title "TRICARE Coverage and Reimbursement of Certain Services Resulting from Temporary Program Changes in Response to the COVID-19 Pandemic,” related to RINs 0720-AB81 and 0720-AB83.

The following provisions are finalized in a consolidated final rule, with modifications: (1) temporary waiver of the exclusion of audio-only telehealth services during the COVID-19 national emergency; (2) temporary waiver of telehealth cost-sharing during the COVID-19 national emergency; (3) temporary waiver of certain provider licensing requirements during the COVID-19 national emergency; (4) temporary waiver of the three-day prior hospital qualifying stay requirements for skilled nursing facilities during the COVID-19 national emergency; (5) temporary waiver of certain acute care hospital requirements for temporary hospitals and freestanding ambulatory surgery centers during the COVID-19 national emergency; (6) temporary revision of diagnosis related group (DRG) reimbursement at a 20 percent higher rate for COVID-19 patients during the COVID-19 Health and Human Services (HHS) Public Health Emergency (PHE); (7) temporary waiver of certain requirements for Long Term Care Hospitals (LTCHs) during the HHS PHE; (8) the permanent adoption of Medicare’s New Technology Add-On Payments (NTAPs) for new medical items and services; and (9) TRICARE’s enactment of the Medicare Hospital Value Based Purchasing (HVBP) Program.  Two provisions of the TRICARE COVID-19 interim final rules are being addressed in a separate final rule: treatment use of investigational drugs under expanded access; and National Institute for Allergy and Infectious Disease (NIAID) sponsored clinical trials.



Agency: Department of Defense(DOD)  Priority: Other Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Final Rule Stage 
Major: No  Unfunded Mandates: No 
CFR Citation: 32 CFR 199   
Legal Authority: 5 U.S.C. 301    10 U.S.C. ch 55   
Legal Deadline:  None
Action Date FR Cite
Interim Final Rule  10/30/2020  85 FR 68753   
Interim Final Rule Effective  10/30/2020 
Interim Final Rule Comment Period End  11/30/2020 
Final Action  06/00/2022 
Regulatory Flexibility Analysis Required: Undetermined  Government Levels Affected: Undetermined 
Federalism: No 
Included in the Regulatory Plan: Yes 
RIN Data Printed in the FR: No 
Related RINs: Related to 0720-AB81, Related to 0720-AB82 
Agency Contact:
Erica Ferron
Defense Health Agency, Medical Benefits and Reimbursement Division
Department of Defense
Office of Assistant Secretary for Health Affairs
16401 E Centretech Parkway,
Aurora, CO 80011-9066
Phone:303 676-3626